首页 > 期刊杂志 > 正文

The value of the "suspicious for urothelial carcinoma" cytology category: A correlative study of 4 years including 337 patients.

“可疑尿路上皮癌”细胞学分类的价值:4 年337例患者的相关研究

Ton Nu TN,Kassouf W,Ahmadi-Kaliji B,Charbonneau M,Auger M,Brimo F

Abstract

The terminology used in reporting urine cytology lacks uniformity and the significance of the "atypical" and "suspicious" categories is still not well established. This results in variable clinical follow-up and management of those cases. The authors sought to investigate the prognostic value of a diagnosis of "suspicious for high-grade urothelial carcinoma" (HGUCA).
All cases with a "suspicious" or "positive" cytological diagnosis spanning 4 years were included and correlated with the subsequent biopsies obtained within 6 months of urine collection.
A total of 447 correlative events (57% positive and 43% suspicious) corresponding to 773 cytology specimens and 337 patients were included. The morphology of the "suspicious" cells was similar to what has recently been reported in the literature as "atypical urothelial cells, cannot exclude HGUCA." A "suspicious" diagnosis was more often rendered than a "positive" one in voided specimens (80% vs 65%, respectively). The mean interval between cytology and biopsy was 31 days. On follow-up, 92% of "suspicious" diagnoses (176 of 191 diagnoses) and 90% of "positive" diagnoses (230 of 256 diagnoses) were found to have a biopsy with a diagnosis of carcinoma (low grade or high grade). A diagnosis of HGUCA followed a "suspicious" and a "positive" diagnosis in 79% and 86% of cases, respectively.
A "suspicious" diagnosis as defined in the current study warrants close investigations and repeat biopsy to rule out HGUCA. In addition, the findings of the current study raise the question of the need for quantitative criteria for diagnosing HGUCA on cytology. Cancer (Cancer Cytopathol) 2014;122:796-803. © 2014 American Cancer Society.

摘要

用于报告尿液细胞学的术语尚缺乏统一性, “非典型性”和“可疑”两类别的意义尚未完全明了。 因此, 导致这类病例的临床随访和处理差异性很大。作者尝试研究“可疑高级别尿路上皮癌”(HGUCA) 诊断的预后价值。

该研究纳入了4年内细胞学诊断为“可疑” 和“阳性”的所有病例, 并与细胞收集后六个月之内的活检进行对照研究。

相关的337例患者、773例细胞学标本中,总计纳入447例细胞学诊断结果 (57% 阳性和43%可疑)。“可疑”细胞的形态与最近文献报道的“非典型尿路上皮细胞, 不能排除高级别尿路上皮癌” 中的细胞很类似。在尿液细胞学诊断中, “可疑”诊断 比“阳性”诊断的比率更高 (分别为80% 和65%)。 细胞学和活检的平均间隔时间为31 天。 随访中,92% “可疑”诊断(191中的176例 ) 和90% “阳性“诊断(256 中的230例)活检最后诊断为癌症(包括低级别或者高级别尿路上皮癌)。在“可疑”和“阳性“细胞学诊断中, 活检诊断为高级别尿路上皮癌(HGUCA)的比率分别为79%和86%。

我们的研究表明: “可疑”细胞学 诊断值得进一步密切随访观察和重复活检以排除高级别尿路上皮癌。另外,目前的研究发现也提出这样一个问题:为细胞学上诊断高级别尿路上皮癌,制定量化标准势在必行。

full text

我要评论

0条评论